| Literature DB >> 30030270 |
Carolina Martínez-Laperche1,2, Elena Buces1,2, M Carmen Aguilera-Morillo3, Antoni Picornell2,4, Milagros González-Rivera4,5, Rosa Lillo3, Nazly Santos6, Beatriz Martín-Antonio7, Vicent Guillem8, José B Nieto9, Marcos González10, Rafael de la Cámara11, Salut Brunet12, Antonio Jiménez-Velasco13, Ildefonso Espigado14, Carlos Vallejo15, Antonia Sampol16, José María Bellón2, David Serrano1,2, Mi Kwon1,2, Jorge Gayoso1,2, Pascual Balsalobre1,2, Álvaro Urbano-Izpizua7, Carlos Solano8, David Gallardo6, José Luis Díez-Martín1,2,17, Juan Romo3, Ismael Buño.
Abstract
Despite considerable advances in our understanding of the pathophysiology of graft-versus-host disease (GVHD), its prediction remains unresolved and depends mainly on clinical data. The aim of this study is to build a predictive model based on clinical variables and cytokine gene polymorphism for predicting acute GVHD (aGVHD) and chronic GVHD (cGVHD) from the analysis of a large cohort of HLA-identical sibling donor allogeneic stem cell transplant (allo-SCT) patients. A total of 25 SNPs in 12 cytokine genes were evaluated in 509 patients. Data were analyzed using a linear regression model and the least absolute shrinkage and selection operator (LASSO). The statistical model was constructed by randomly selecting 85% of cases (training set), and the predictive ability was confirmed based on the remaining 15% of cases (test set). Models including clinical and genetic variables (CG-M) predicted severe aGVHD significantly better than models including only clinical variables (C-M) or only genetic variables (G-M). For grades 3-4 aGVHD, the correct classification rates (CCR1) were: 100% for CG-M, 88% for G-M, and 50% for C-M. On the other hand, CG-M and G-M predicted extensive cGVHD better than C-M (CCR1: 80% vs. 66.7%, respectively). A risk score was calculated based on LASSO multivariate analyses. It was able to correctly stratify patients who developed grades 3-4 aGVHD (P < .001) and extensive cGVHD (P < .001). The novel predictive models proposed here improve the prediction of severe GVHD after allo-SCT. This approach could facilitate personalized risk-adapted clinical management of patients undergoing allo-SCT.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30030270 PMCID: PMC6058238 DOI: 10.1182/bloodadvances.2017011502
Source DB: PubMed Journal: Blood Adv ISSN: 2473-9529